Researchers Discover Promising New Anticancer Strategy LA JOLLA, Calif. Nov. 7, 2017 Scientists at The Scripps Research Institute (TSRI) have discovered a compound that in laboratory tests irreversibly stops the growth of certain aggressive, treatment-resistant tumor cells. If successfully developed into a treatment, the compound would be the first of a new class of anticancer drugs.
In their study, published in the Proceedings of the National Academy of Sciences, the TSRI researchers showed that the new compound, FiVe1, blocks the growth of tumor cells that have undergone what researchers call the epithelial-mesenchymal transition (EMT), a process common in breast, colon, lung and other epithelial cell-derived tumors known as carcinomas.
FiVe1 also blocks the growth of tumors called sarcomas, which originate from mesenchymal tissues including bone, fat, cartilage, muscle and blood vessels. The compound blocks cell division (mitosis) by binding to a structural protein, vimentin, that is produced abundantly in mesenchymal-type cells. Drugs that work via this mechanism should spare many of the healthy, fast-dividing cells, such as hair follicle cells, that are harmed by standard chemotherapy drugs.
We hope that this discovery is going to lead to the development of effective therapies against a broad range of aggressive cancers, said principal investigator Luke Lairson, Ph.D., assistant professor of chemistry at TSRI.
A Dangerous Cell Type
Mesenchymal cells are one of the major cell types in developing embryos, and ultimately give rise to bone, muscle, fat, and certain other tissues. The EMT occurs naturally in early development to turn some epithelial cells another broad cell type into more free-ranging mesenchymal cells. The EMT also can be triggered by inflammation in adult tissues to transform epithelial cells into stem-like mesenchymal cells that aid wound healing.
The vast majority of cancer deaths are ultimately caused by recurrence following therapy or metastases. In previous studies, scientists had demonstrated that the EMT process enables carcinoma cells to adopt the properties of cancer stem cells, namely chemotherapy resistance and the ability to migrate in the body to form metastases.
Researchers have become aware in just the last decade that breast, colon and other epithelial-derived tumor cells sometimes exploit the EMT to detach from a primary tumor and acquire stem-like properties. Whether they originate from EMT-transformed epithelial cells or from mesenchymal tissues, mesenchymal cancer cells are prone to form deadly metastases and are generally difficult to treat with drugs surgical removal is often the only good option.
The TSRI researchers, including lead author Michael J. Bollong, Ph.D., currently a Scripps Fellow in the Department of Chemistry, discovered FiVe1 by screening a library of about 50,000 small-molecule compounds for activity against EMT-transformed breast cancer cells. The engineered cell line was developed by collaborating researcher Sendurai A. Mani, Ph.D., of M.D. Anderson Cancer Center at the University of Texas. The cells express FOXC2, a transcription factor gene that promotes the EMT and makes cancer cells more stem-like, more prone to metastasis and more resistant to treatment.
One compound performed particularly well at curbing the growth of the FOXC2-expressing cells without affecting non-FOXC2-expressing cells, and had other properties that make it potentially suitable as a small-molecule drug. Follow-up molecular biology studies revealed that the compound blocks mitosis in the FOXC2-expressing cancer cells by binding to a structural protein called vimentin, produced principally in mesenchymal cell types. The compound, in addition to blocking mitosis, caused EMT-transformed breast cancer cells to quickly revert to a lower-grade, epithelial appearance. Lairson and colleagues named the compound FOXC2-inhibiting Vimentin effector 1 (FiVe1).
Traditional anti-mitosis drugs target proteins such as microtubules that are basic features of the cell division apparatus, Bollong said. We've shown for the first time here that targeting an intermediate filament protein such as vimentin can also induce mitotic catastrophe.'
Further lab-dish tests showed that FiVe1 irreversibly blocks mitosis in several other EMT-transformed cancer cell lines, as well as in tumor cells originating from muscle, fat, cartilage and other mesenchymal tissues.
FiVe1's selectivity for vimentin-containing mesenchymal cancer cells means that it wouldn't have the same side-effects as traditional chemotherapy drugs. Vimentin is not expressed at significant levels in the hair follicle cells and mouth- and gut-lining epithelial cells damaged by standard chemotherapy drugs. A drug that blocks mitosis by targeting vimentin should be less toxic than traditional chemotherapeutic drugs that targets cell-division, Lairson said.
He and his colleagues envision future drugs based on this strategy being used against carcinomas as add-on therapies to suppress EMT-transformed tumor cells that are prone to metastasize. Against sarcomas tumors that are entirely mesenchymal anti-vimentin drugs could be primary therapies.
The researchers currently are working to optimize FiVe1 and a few other promising compounds with chemical modifications. With help from a new National Institutes of Health grant they also are screening larger compound libraries to find other potential drug compounds that selectively attack mesenchymal and EMT-transformed cancers. The team plans to begin tests in animal models of cancer once they have an optimized compound.
Other co-authors of the study, A vimentin-binding small molecule leads to mitotic disruption in mesenchymal cancers, were Mika Pietil , Tapasree Roy Sarkar, and Rama Soundararajan of the Mani Laboratory at M.D. Anderson; an
Most recent headlines
11/12/2025
Dalet, a leading provider of cloud-native, end-to-end media workflow solutions, ...
28/11/2025
Nadia Fall attends the 2025 Sundance Film Festival premiere of Brides at the Egyptian Theatre on January 24, 2025, in Park City, Utah. (Photo by Donyale West/...
28/11/2025
It's easy to ignore those little red update available badges. But when it ...
28/11/2025
WASHINGTON Federal Communications Commission has released a tentative agenda for the December Open Commission Meeting scheduled for Thursday, December 18, 2025 ...
28/11/2025
The Professional Fighters League is looking to super-serve fans of mixed martial...
28/11/2025
Fubo has released in beta on select Roku devices a new feature that lets users display up to four simultaneous streams at once....
28/11/2025
The WNBA playoffs and Week 4 of the NFL regular season highlight the list of live sports events airing on television this weekend....
28/11/2025
The 32nd class of honorees to the B+C Hall of Fame took to the stage at New York's Ziegfeld Ballroom on September 26 for a gala induction event. Click below...
28/11/2025
We hold in our hands the very last Next Text for Next TV, the weekly back-and-fo...
28/11/2025
DirecTV said it made a deal with EchoStar to buy EchoStar's video businesses, including satellite-TV provider Dish TV and virtual MVPD Sling TV, for $1 plus...
28/11/2025
The Broadcasting+Cable Hall of Fame, the premier industry event paying tribute to the influencers, innovators and shining lights of broadcast, cable and streami...
28/11/2025
Friday 28 November 2025
Sky Sports x Slawn drop limited-edition football jersey...
28/11/2025
Rohde & Schwarz shows resilience in a challenging environment, revenue exceeds t...
28/11/2025
Unwrapped: The Toy Show Appeal - airing this Sunday on RT One and RT Player- s...
27/11/2025
LONDON Vizrt has added several AI-driven advanced features offering improved speed, intelligence and accuracy in the newest version of its media asset managemen...
27/11/2025
Prime Video has launched AI-powered video season recaps in a beta version for select English-language Prime Original series in the U.S., a move Amazon is callin...
27/11/2025
Back to All News
Netflix's Raat Akeli Hai: The Bansal Murders Marks a Grand...
27/11/2025
27 Nov 2025
GSMA brings M360 Eurasia 2026 to Samarkand in partnership with VEON...
27/11/2025
Tahar Rahim and Izuka Hoyle star in the gripping six-part Sky Original from Acad...
27/11/2025
Thursday 27 November 2025
Sky Arts Reveals the Nation's Greatest Basslines - and Queen Reign Supreme
The UK's most iconic basslines have been revealed...
27/11/2025
Back to All News
Stranger Things 5': Prepare for One Last Adventure With O...
27/11/2025
The media industry has a paradox at its core. It's an industry built on light, color and imagination, yet behind the scenes, it's powered by one of the ...
27/11/2025
Rating reflects rating progress across areas including policies, diversity & inclusion, health & safety and Net Zero leadership
Winchester, UK, 27 November 202...
27/11/2025
What are the industry standards for Retail Media? Kathryn explains that certification is based on the IAB Europe Retail Media Measurement Standards and the IAB ...
27/11/2025
World champion boxer and Irish sporting icon Katie Taylor will be in studio this...
27/11/2025
Roblox, one of the world's most popular online gaming platforms for primary ...
27/11/2025
Black Friday is leveling up. Get ready to score one of the biggest deals of the season - 50% off the first three months of a new GeForce NOW Ultimate membership...
26/11/2025
SVG Sit-Down: Prime Video EP Mike Muriano Previews Massive Black Friday Slate Fe...
26/11/2025
A cinematic snow sculpture at the 1995 Sundance Film Festival. Photo by Randall Michelson...
26/11/2025
Book podcasts are booming. On Spotify, you'll find everything from celebrity book clubs to deep dives with bestselling authors. And in markets where audiobo...
26/11/2025
Mumbai, November 24, 2025: In a first-of-its-kind initiative, JioStar, in collab...
26/11/2025
LONDON Factual content producer ITN Productions has launched a new low-latency IP gallery for news bulletins....
26/11/2025
MIAMI TelevisaUnivision said it struck a new multiyear distribution agreement with YouTube TV that includes distribution of TelevisaUnivision's U.S. network...
26/11/2025
OpenDrives, Inc., a leader in software-defined data storage and data services, today announced the launch of the Atlas Corporate Creative Solution. This new Atl...
26/11/2025
Disguise, the industry-leading company powering the world's biggest live performances, is partnering with pioneering LED wall manufacturer DVS to give atten...
26/11/2025
HighField AI, the pioneer in agentic and multimodal automation for broadcast and media production, today announced the expansion of its global channel partner n...
26/11/2025
As high-stakes Premier League fixtures approach and additional premium content launches, with MONO positioning themselves to dominate Thailand's sports stre...
26/11/2025
Hosting a wide variety of events from high-intensity NHL games to complex live music concerts and major entertainment productions, Montreal's 21,000 capacit...
26/11/2025
Vizrt, the leader in live production technology revolutionizing viewer engagement and experience, releases AI-driven advances focusing on speed, intelligence, a...
26/11/2025
ITN Productions, an award-winning factual content producer, today launched a new low-latency IP gallery for news bulletins. Responsible for delivering a leading...
26/11/2025
Ikegami reports ongoing advances throughout 2025 in developing and delivering coordinated television production solutions that maximize quality, versatility and...
26/11/2025
Following the Nov. 21 blackout of NBCUniversal channels on Fubo, the two sides have traded barbs about their inability to reach a new carriage deal....
26/11/2025
LONDON As TV sports rights become increasingly important for both broadcasters and streamers, Ampere Analysis predicts global investment in the genre will surpa...
26/11/2025
LOS ANGELES Vubiquity said it has achieved the Amazon Web Services (AWS) Media & Entertainment Competency as part of the AWS Partner Network (APN). This designa...
26/11/2025
WASHINGTON The Federal Communications Commission's Enforcement Bureau said it has entered into a consent decree with Comcast calling for the cable company t...
26/11/2025
Berklee Named to the Hollywood Reporters Top Music Schools List The publication highlights the college's screen scoring program, industry partnerships, and ...
26/11/2025
Back to All News
Animated Series Love Through a Prism' Casts New Light on ...
26/11/2025
Back to All News
NALIP Unveils Fifth Cohort of Director Incubator
Social Impact
26 November 2025
United States
Link copied to clipboard
The National Assoc...
26/11/2025
YouView Achieves Greenly Gold Certification for SustainabilityNov 26, 2025
YouView is proud to announce a Gold Certification award from Greenly for our perform...
Researchers Discover Promising New Anticancer Strategy LA JOLLA, Calif. Nov. 7, 2017 Scientists at The Scripps Research Institute (TSRI) have discovered a compound that in laboratory tests irreversibly stops the growth of certain aggressive, treatment-resistant tumor cells. If successfully developed into a treatment, the compound would be the first of a new class of anticancer drugs.
